Survodutide: Results, Side Effects, Heart Safety, FDA Status

The short answer

Survodutide (BI 456906) is an experimental once-weekly shot from Boehringer Ingelheim, licensed from Zealand Pharma, that turns on both the glucagon and GLP-1 receptors. In the Phase 3 SYNCHRONIZE-1 trial, adults without diabetes lost 12.2% to 13.0% of their weight at 76 weeks counting everyone (up to 16.6% if they stayed on it), and on November 9, 2026 the SYNCHRONIZE-CVOT trial showed it did not raise heart risk versus placebo. It is not FDA approved; Boehringer says it is preparing regulatory filings for obesity. On any GLP-1 drug, the muscle you keep is up to you, and Sharpy gives you one protein target and one 20-minute workout a day.

What is survodutide, and should you care? Survodutide is an experimental weekly shot for obesity and fatty liver disease made by Boehringer Ingelheim. It is a "dual agonist": it turns on the GLP-1 receptor, like Wegovy, and also the glucagon receptor. In Phase 3 trials, people lost 12% to 13% of their weight on average over 76 weeks, and up to 16.6% if they stayed on it. It is not approved yet.

Survodutide is in the news today, November 9, 2026, because its heart safety trial, SYNCHRONIZE-CVOT, was presented at the American Heart Association meeting and published in The Lancet. That was the last piece of the obesity program, and Boehringer says it is now preparing to file with regulators.

What is survodutide? The basics

Question Answer
Name Survodutide (code BI 456906)
Maker Boehringer Ingelheim, licensed from Zealand Pharma
Drug type Glucagon/GLP-1 receptor dual agonist
How it is taken Shot under the skin, once a week
Doses tested in Phase 3 3.6 mg and 6.0 mg
Brand name None yet
FDA status (Nov 9, 2026) Not approved; filings being prepared for obesity
MASH status FDA Fast Track (2021) and Breakthrough Therapy (2024); Phase 3 LIVERAGE trials running
Price None. It is not for sale

How does survodutide work? (mechanism of action)

GLP-1 is the gut hormone behind Ozempic and Wegovy. It slows the stomach and turns down hunger. Glucagon is a different hormone. Boehringer says the glucagon side is linked to energy use and liver fat. The idea is that the GLP-1 side helps you eat less while the glucagon side works more directly on the liver.

That is why survodutide is being tested for MASH (fatty liver with inflammation) as well as weight. Glucagon on its own raises blood sugar, so pairing it with GLP-1 is meant to balance that out.

Survodutide Phase 3 results: the SYNCHRONIZE trials

Trial results can be shown two ways. The "treatment-regimen" number counts everyone who started, including people who quit. The "efficacy" number shows what happened in people who stayed on the drug. Both matter, so here are both where they were reported.

Trial Who was in it Length Survodutide Placebo
SYNCHRONIZE-1 725 adults with obesity, no type 2 diabetes 76 weeks 12.2% (3.6 mg), 13.0% (6.0 mg) counting everyone; 15.3% and 16.6% if staying on 5.4% counting everyone; 3.2% if staying on
SYNCHRONIZE-2 755 adults with obesity and type 2 diabetes 76 weeks Up to 13.1%; A1C down up to 1.21 points 3.1%; A1C down 0.03
SYNCHRONIZE-MASLD 218 adults with obesity and fatty liver 48 weeks 84.2% cut liver fat by 30% or more; weight down up to 12.2% 24.3%; weight down 1.0%
SYNCHRONIZE-CVOT 5,530 adults with heart disease, kidney disease or risk factors 72 weeks (weight) Up to 13.7% weight loss 2.0%

One catch in SYNCHRONIZE-1: the placebo group lost more than expected. Investigators said more than 16% of people on placebo reported using a GLP-1 drug they were not supposed to take during the trial. That pulls the gap between drug and placebo closer.

Survodutide heart safety: what SYNCHRONIZE-CVOT found

This is today's news. The trial tracked five kinds of heart events: heart-related death, heart attack, stroke, procedures to reopen heart arteries, and heart failure events.

  • Main result: survodutide did not raise the risk of these events versus placebo. The hazard ratio was 0.89 (95% CI 0.67 to 1.18).
  • What that means: the drug passed its safety test. Because the range crosses 1.0, the trial does not show that survodutide lowers heart risk. It shows it did not raise it.
  • Other results: systolic blood pressure fell up to 6.68 points versus 1.76 on placebo, and waist size shrank up to 11.96 cm (about 4.7 inches) versus 2.74 cm. CRP, an inflammation marker, and triglycerides also fell.

For comparison, Wegovy has a heart benefit on its label from the SELECT trial. Survodutide's trial was built to prove safety, not benefit, so the two are not the same claim.

Survodutide side effects

The side effects look like the rest of the GLP-1 family, but the dropout rate stands out.

Trial Stopped due to stomach side effects (survodutide) Placebo
SYNCHRONIZE-1 17.8% (3.6 mg), 20.2% (6.0 mg) 2.9%
SYNCHRONIZE-2 Up to 18% 1.2%
SYNCHRONIZE-CVOT 19.3% (3.6 mg), 20.8% (6.0 mg) 1.9%

The most common were nausea, vomiting, diarrhea and constipation, mostly mild to moderate. Most people who quit did so while the dose was going up. Boehringer said the early trial rules gave doctors little room to slow the dose increase, and its newer studies (SYNCHRONIZE-START, SYNCHRONIZE-HERA, ELEVATE-LIVER) allow more flexible dosing. Heart rate went up about 3.2 to 3.5 beats per minute in SYNCHRONIZE-1, which is also seen with other drugs in this class.

If nausea is what you are fighting on your current drug, our guide to managing nausea on Ozempic has steps that apply to any GLP-1.

Does survodutide cause muscle loss?

All big weight loss takes some muscle with it. In a small MRI substudy of SYNCHRONIZE-1, visceral (belly) fat fell 34.0% on 6.0 mg and liver fat fell 63.1%, while lean body volume fell 9.8%. Investigators reported that most of the tissue lost was fat. That is encouraging, but it was 25 people per group, and lean volume still went down.

This is where daily habits matter more than the drug name. Eating enough protein and lifting a few times a week are the two proven ways to keep lean mass. Sharpy turns that into one protein target and one 20-minute strength workout a day, plus a Shape Score so you can see whether you are losing fat or muscle. For the training side, start with resistance training on GLP-1.

Survodutide vs tirzepatide, retatrutide and mazdutide

None of these have been tested head to head against survodutide, so treat this as a rough map, not a ranking.

Drug Receptors Maker Status (Nov 2026) Key result
Survodutide Glucagon + GLP-1 Boehringer Ingelheim Not approved 12.2% to 13.0% at 76 weeks, everyone counted (SYNCHRONIZE-1)
Tirzepatide (Zepbound) GIP + GLP-1 Eli Lilly FDA approved 20.9% at 72 weeks on 15 mg (SURMOUNT-1)
Semaglutide (Wegovy) GLP-1 Novo Nordisk FDA approved 14.9% at 68 weeks (STEP 1)
Retatrutide GIP + GLP-1 + glucagon Eli Lilly Not approved 28.3% at 80 weeks on 12 mg, if staying on (TRIUMPH-1)
Mazdutide Glucagon + GLP-1 Innovent (China), Lilly elsewhere Approved in China, June 2025 14.8% at 48 weeks on 6 mg (GLORY-1)

Survodutide's pitch is less about beating Zepbound on the scale and more about the liver. If its LIVERAGE trials succeed, it could compete with Wegovy for MASH. For the approved drugs today, see semaglutide vs tirzepatide. For the other new shots, see retatrutide vs semaglutide vs tirzepatide and MariTide. Our mazdutide guide covers the other glucagon and GLP-1 shot, which is already approved in China. Another China-approved shot, efsubaglutide alfa, was licensed for new markets in November 2026.

Survodutide launch date: when could it be available?

There is no date. Boehringer has said it is preparing regulatory submissions for obesity but has not said when it will file with the FDA or EMA. A standard FDA review takes about 10 months after a filing is accepted, and a priority review about 6 months. So even a fast path puts a US launch after a filing that has not yet been announced. There is no brand name and no price.

If you want to try it now, the only legitimate route is a clinical trial. You can search ClinicalTrials.gov for "survodutide." Do not buy "survodutide peptide" online; those products are unapproved and untested.

Bottom line

Survodutide is a real, late-stage drug with solid Phase 3 data: about 12% to 16% weight loss, big drops in liver fat, and now proof that it does not raise heart risk. It is not approved, it causes more stomach-related quitting than many people would like, and it does not yet beat tirzepatide on weight. If you are on a GLP-1 today, talk to your prescriber before planning around a drug that is not on the market. Meanwhile, keep the muscle you have with Sharpy.

Sources

Questions people ask

What is survodutide?

Survodutide (code BI 456906) is an investigational weight-loss and liver drug from Boehringer Ingelheim. Zealand Pharma discovered it and licensed it to Boehringer, which runs development and sales worldwide. It activates two hormone receptors, glucagon and GLP-1, and is given as a shot under the skin once a week.

Is survodutide FDA approved?

No. As of November 9, 2026, survodutide is not approved anywhere. Boehringer said that, based on the full SYNCHRONIZE program, it is moving forward with preparations for regulatory submissions in obesity. It has not given a filing or approval date. For liver disease (MASH), the FDA gave it Fast Track in 2021 and Breakthrough Therapy designation in 2024.

How much weight do you lose on survodutide?

In SYNCHRONIZE-1 (725 adults without type 2 diabetes, 76 weeks), average loss was 12.2% on 3.6 mg and 13.0% on 6.0 mg versus 5.4% on placebo, counting everyone who started. For people who stayed on treatment, it was 15.3% and 16.6% versus 3.2%. In SYNCHRONIZE-2 (adults with type 2 diabetes), loss reached up to 13.1% versus 3.1%.

What are the side effects of survodutide?

Stomach and gut problems were the most common: nausea, vomiting, diarrhea and constipation, mostly mild to moderate and mostly during dose increases. They were serious enough that about 18% to 21% of people on survodutide stopped treatment because of them, versus 1% to 3% on placebo. Heart rate rose by about 3 beats per minute in SYNCHRONIZE-1.

Survodutide vs tirzepatide: which works better?

They have not been tested against each other. Tirzepatide 15 mg produced about 20.9% loss at 72 weeks in SURMOUNT-1. Survodutide produced up to 13.0% at 76 weeks in SYNCHRONIZE-1 by the same "everyone who started" method, but its placebo group lost an unusually high 5.4%, partly because some placebo patients used other GLP-1 drugs. Separate trials cannot settle which is stronger.

Survodutide vs retatrutide: what is the difference?

Survodutide hits two receptors (glucagon and GLP-1). Retatrutide, from Eli Lilly, hits three (GIP, GLP-1 and glucagon). In its TRIUMPH-1 trial, retatrutide 12 mg produced 28.3% loss at 80 weeks in people who stayed on it, a larger number than survodutide has shown. Neither is approved.

Can I buy survodutide peptide online?

Survodutide is not approved, so there is no legal pharmacy version. Products sold online as survodutide "research peptide" are not FDA approved, are not checked for purity or dose, and are not meant for people. The only legitimate way to get it right now is through a clinical trial.

Read next